A monoclonal antibody targeting vascular endothelial growth factor, was approved as antiangiogenic therapy. Antiangiogenesis therapy is one of two types of drugs in a new class of medicines that restores health by controlling blood vessel growth.The other medication is called pro-angiogenic therapy. Antiangiogenic therapy inhibits the growth of new blood vessels. Because new blood vessel growth plays a critical role in many disease conditions, including disorders that cause blindness, arthritis, and cancer.
Related journals of Antiangiogenic Therapies
Journal of Oncology Translational Research, Nuclear Medicine & Radiation Therapy, Chemotherapy: Open Access, Cancer Medicine & Anti Cancer Drugs, Cancer Diagnosis, Cancer Gene Therapy, Cancer Gene Therapy Week, Gene Therapy, Integrative Cancer Therapies, Cancer Therapy, Current Cancer Therapy Reviews.
Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To cite this article:
Jan 01, 1970
Accepted Date: Jan 01, 1970
Published Date: Jan 01, 1970